To include your compound in the COVID-19 Resource Center, submit it here.

How cancer play Pi plans to deploy $19.7M series B

Existing investor Pontifax led a $19.7 million series B round for Pi, which is developing protein degradation modulators for drug-resistant multiple myeloma and solid tumor indications based on technology licensed from

Read the full 315 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers